BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 27932139)

  • 1. De Novo Anti-HLA Antibodies After Heart Transplantation Are Associated With Adverse Events in the Long-term Follow-up of Cardiac Transplant Recipients.
    Solé-González E; Mirabet S; Brossa V; López-López L; Rivas-Lasarte M; Capellades-Olivella H; Ginel-Iglesias AJ; Martorell-Pons J; Roig E
    Transplant Proc; 2016 Nov; 48(9):3030-3032. PubMed ID: 27932139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donor-specific anti-HLA antibodies with antibody-mediated rejection and long-term outcomes following heart transplantation.
    Clerkin KJ; Farr MA; Restaino SW; Zorn E; Latif F; Vasilescu ER; Marboe CC; Colombo PC; Mancini DM
    J Heart Lung Transplant; 2017 May; 36(5):540-545. PubMed ID: 27916323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor-specific antibodies to human leukocyte antigens are associated with and precede antibodies to major histocompatibility complex class I-related chain A in antibody-mediated rejection and cardiac allograft vasculopathy after human cardiac transplantation.
    Nath DS; Angaswamy N; Basha HI; Phelan D; Moazami N; Ewald GA; Mohanakumar T
    Hum Immunol; 2010 Dec; 71(12):1191-6. PubMed ID: 20868717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donor-specific HLA alloantibodies: Impact on cardiac allograft vasculopathy, rejection, and survival after pediatric heart transplantation.
    Tran A; Fixler D; Huang R; Meza T; Lacelle C; Das BB
    J Heart Lung Transplant; 2016 Jan; 35(1):87-91. PubMed ID: 26422083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased negative impact of donor HLA-specific together with non-HLA-specific antibodies on graft outcome.
    Reinsmoen NL; Lai CH; Mirocha J; Cao K; Ong G; Naim M; Wang Q; Haas M; Rafiei M; Czer L; Patel J; Kobashigawa J
    Transplantation; 2014 Mar; 97(5):595-601. PubMed ID: 24162250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant.
    Kaczmarek I; Deutsch MA; Kauke T; Beiras-Fernandez A; Schmoeckel M; Vicol C; Sodian R; Reichart B; Spannagl M; Ueberfuhr P
    Exp Clin Transplant; 2008 Sep; 6(3):229-35. PubMed ID: 18954302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody.
    Hodges AM; Lyster H; McDermott A; Rice AJ; Smith JD; Rose ML; Banner NR
    Transplantation; 2012 Mar; 93(6):650-6. PubMed ID: 22245878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poor graft outcome in recipients with de novo donor-specific anti-HLA antibodies after living related kidney transplantation.
    Li X; Ishida H; Yamaguchi Y; Tanabe K
    Transpl Int; 2008 Dec; 21(12):1145-52. PubMed ID: 18803618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. De novo DQ donor-specific antibodies are associated with worse outcomes compared to non-DQ de novo donor-specific antibodies following heart transplantation.
    Cole RT; Gandhi J; Bray RA; Gebel HM; Morris A; McCue A; Yin M; Laskar SR; Book W; Jokhadar M; Smith A; Nguyen D; Vega JD; Gupta D
    Clin Transplant; 2017 Apr; 31(4):. PubMed ID: 28181305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donor-specific HLA antibodies in paediatric cardiac transplant recipients are associated with poor graft survival.
    Irving C; Carter V; Parry G; Hasan A; Kirk R
    Pediatr Transplant; 2011 Mar; 15(2):193-7. PubMed ID: 21199210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
    Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
    Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre- and posttransplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival.
    Ho EK; Vlad G; Vasilescu ER; de la Torre L; Colovai AI; Burke E; Deng M; Schwartz J; Marboe C; Mancini D; Opelz G; Suciu-Foca N
    Hum Immunol; 2011 Jan; 72(1):5-10. PubMed ID: 20971146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of children undergoing cardiac transplantation with high Panel Reactive Antibodies.
    Asante-Korang A; Jacobs JP; Ringewald J; Carapellucci J; Rosenberg K; McKenna D; McCormack J; Wilmot I; Gjeldum A; Lopez-Cepero M; Sleasman J
    Cardiol Young; 2011 Dec; 21 Suppl 2():124-32. PubMed ID: 22152539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel insights into pretransplant allosensitization in heart transplant recipients in the contemporary era of immunosuppression and rejection surveillance.
    Svobodova E; Gazdic T; Kubanek M; Vymetalova J; Voska L; Kment M; Lanska V; Kolesar L; Urban M; Netuka I; Pirk J; Melenovsky V; Kautzner J; Slavcev A; Malek I
    Transpl Int; 2016 Jan; 29(1):63-72. PubMed ID: 26340387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
    Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
    Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Human Leukocyte Antigen (HLA) Antibodies Against Vascular Homograft Donor in Pediatric Heart Transplant Recipients.
    Jahnukainen T; Lauronen J; Raissadati A; Pihkala JI; Ylinen E; Puntila JT; Salminen JT; Pätilä T; Mattila IP; Jalanko HJ
    Ann Transplant; 2019 Aug; 24():454-460. PubMed ID: 31383839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donor-specific antibodies are associated with micro- and macrovascular coronary disease, restrictive myocardial damage, and poor outcome in heart-transplanted patients.
    Clemmensen TS; Koefoed-Nielsen P; Jensen LA; Poulsen SH; Holm NR; Løgstrup BB; Christiansen EH; Dijkstra J; Valen KPB; Eiskjaer H
    Clin Transplant; 2017 Sep; 31(9):. PubMed ID: 28627046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of immune responses to cardiac self-antigens myosin and vimentin in human cardiac allograft recipients with antibody-mediated rejection and cardiac allograft vasculopathy.
    Nath DS; Ilias Basha H; Tiriveedhi V; Alur C; Phelan D; Ewald GA; Moazami N; Mohanakumar T
    J Heart Lung Transplant; 2010 Nov; 29(11):1277-85. PubMed ID: 20615726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of anti-HLA antibodies associated with ventricular assist device use in pediatric patients: A United Network for Organ Sharing database analysis.
    Magdo HS; Schumacher KR; Yu S; Gajarski RJ; Friedland-Little JM
    Pediatr Transplant; 2017 Aug; 21(5):. PubMed ID: 28568969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term prognostic value of elevated heart rate one year after heart transplantation.
    Castel MÁ; Roig E; Rios J; Tomas C; Mirabet S; Cardona M; Brossa V; López L; Vargas L; Sionis A; Vallejos I; Pérez-Villa F
    Int J Cardiol; 2013 Oct; 168(3):2003-7. PubMed ID: 23336956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.